The Food and Drug Administration modified the clinical hold on Tekmira Pharmaceuticals Corp.'s (Nasdaq: TKMR) Ebola treatment to allow for possible use in humans. The stock price leaped $5.38 to $19.65.
Clinical hold on Tekmira's Ebola treatment modified
August 08, 2014 at 14:00 PM EDT
